Piroxicam (Standard)
Based on 1 Customer Validation
Piroxicam (Standard) is the analytical standard of Piroxicam. This product is intended for research and analytical applications. Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.
For research use only. We do not sell to patients.
- Purity: 99.71%
- CAS No.: 36322-90-4
- Formula: C₁₅H₁₃N₃O₄S
- Molecular Weight:331.35
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 36322-90-4
-
Appearance Solid
-
Molecular Weight 331.35
-
Formula C₁₅H₁₃N₃O₄S
-
Color Off-white to light yellow
-
SMILES
O=C(C1=C(O)C2=CC=CC=C2S(N1C)(=O)=O)NC3=NC=CC=C3
-
Synonyms
CP-16171 (Standard)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
SDS (312 KB)
- English - EN (312 KB)
- Français - FR (312 KB)
- Deutsch - DE (312 KB)
- Norwegian - NO (312 KB)
- Español - ES (312 KB)
- Swedish - SV (312 KB)
- Italian - IT (312 KB)
- Korean - KR (312 KB)
- Portuguese - PT (312 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kato M, et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol. 2001 Dec;53(12):1679-85. [Content Brief]
[2]. Mohammed SI, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002 Jan 15;62(2):356-8. [Content Brief]
[3]. Silva J, et al. Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines. Anticancer Res. 2017 Apr;37(4):1737-1745. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Piroxicam (Standard) Related Classifications
HY-B0253R Related Classifications
Powered by Bioz